for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

EU clears Bristol-Myers immunotherapy drug for blood cancer

LONDON (Reuters) - Bristol-Myers Squibb’s immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday.

Opdivo is already approved for melanoma, lung cancer and kidney cancer.

Reporting by Ben Hirschler. Editing by Jane Merriman

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up